Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - TABLETS FOR ACUTE TREATMENT OF MIGRAINE ATTACKS

US FDA approval for Orchid's ceftriaxone vials

 

BY OUR PHARMA  CORRESPONDENT

4 August, 2005: Orchid Chemicals & Pharmaceuticals Ltd has received the formal approval from the US FDA for its generic ceftriaxone ANDA. The marketing approval has been granted for ceftriaxone for injection, 250mg, 500mg, 1gm and 2gm single-dose vials, 1gm and 2gm piggyback vials and 10gm/100 ml pharmacy bulk package vials. 

The Chennai (India)-based Orchid will distribute its ceftriaxone generic formulations in the US exclusively through Apotex Corp. The company has already shipped the product to the US in sufficient quantities based on prior FDA clearance. Apotex will start distribution of the products to its customers from the day of approval, said an Orchid release. 

Ceftriaxone is an injectable third generation cephalosporin antibiotic that went off-patent recently. The estimated annual retail sales of this product was around USD 700 million prior to patent expiry. 

The company has received the USFDA approval for its Ceftriaxone generic within 13 months of its ANDA submission. This is the third cephalosporin ANDA approval the company has received in recent months. The company expects more ANDA approvals to follow in the months to come. As of date, the company has filed 19 ANDAs with the US FDA. 

Orchid Chemicals & Pharmaceuticals Ltd has diversified competencies in bulk drugs, formulations and drug discovery. The company has achieved a turnover and operating income of Rs 170.26 crore for the quarter ended June 30, 2005 (Q1 FY 05-06) in comparison to Rs 173.86 crore registered during the corresponding first quarter of last fiscal. Gross profit before interest, depreciation and extraordinary items was Rs 45.86 crore compared to Rs 37.24 crore during the corresponding quarter of last year. Profit before tax was Rs 8.19 crore as against Rs 5.09 crore of the Q1 of last fiscal, despite higher outgo on depreciation (Rs 16.91 crore as against Rs 15.29 crore) and interest (Rs 20.76 crore as against Rs 16.86 crore). Net profit after tax registered a robust growth of 56% and stood at Rs 7.33 crore compared to Rs 4.69 crore of Q1 last fiscal.

Orchid’s US generics business is poised to take off from the second quarter with the introduction in the market of products which have received the USFDA approval. The company received two ANDA approvals from the USFDA, for cefazolin injections and cephalexin capsules during the quarter. Besides ceftriaxone injections, this fiscal expects the launch of cefprozil tablets, that is going off-patent.

The cumulative count of DMFs and ANDAs at the end of the quarter stood at 18 and 19 respectively. More filings are planned in the balance quarters of this fiscal to nearly double the regulatory filings count, a company statement said.

BY OUR PHARMA  CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

More funding for Sentinel Breastscan

New drug Provigil can keep you awake: Cephalon

Anti-virals can stem global flu outbreak: Studies

USFDA’s recall overdrive creates panic among drug users

Backjoy - A chair support that helps relieve back pain

Why does mammography lead to pain for some black women?

What after the Atkins diet?

Perrigo recalls infants’ oral drops in US

Diovan approved to treat heart failure in US

British Pharma seeks opinion on industry code

Novartis gets EU nod for Xolair

Eli Lilly to submit ruboxistaurin for diabetic vision loss

Snuppy: The first cloned dog

India bans valdecoxib

UK recalls Lipitor fakes

Drug developers set sight on 'interactome'

Ranbaxy gets US FDA nod for sumatriptan tabs

US FDA approval for Orchid's ceftriaxone vials

Pfizer's Celebrex approved for spondilitis

IVAX gets FDA okay for hydrochlorothiazide caps

Mumbai floods: Pharma sector losses estimated at Rs 1,000 crore

Calorie Control Council Statement: Allegations Against Aspartame Unfounded

European biotech start-ups fail to win late-stage funds

Ranbaxy gets USFDA nod for glimepiride tabs

Experts debate benefits of heart implant in US

US FDA blocks sale of Pharmakon's illegal drugs

Echinacea does not prevent common cold: Study

Afghan’s first generics plant to go on stream by Oct. ‘05

PhRMA seeks voluntary DTC ad code

Barr, Teva get fexofenadine approvals from US FDA

Novartis completes Eon Labs buy

Able Laboratories files bankruptcy suit with US court

Orbus inks supply pact with Docpharma 

Matrix acquires controlling stake in Docpharma

Actavis launches Fosinopril in Netherlands, Sweden &UK; Benazepril in Germany

Insomnia treatment: ROZEREM approved by FDA

Stories below archived on 25 July, 2005

Roche, Novartis lead on novel cancer therapies

US FDA grants fast track status for GSK’s HIV drug

Stem Cell Bill could be delayed in US

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Lupin launches generic ceftriaxone in US

Hormonal contraceptives safe for long-term use: WHO

Abortion pill to carry 'black box' warning

Vaccines not linked to autism, say experts

Novartis acquires Bristol-Myers’ OTC business in US

Guidant alerts on flaw in pacemakers

Awareness on Medicare drug benefit scheme low in US

NIH review finds govt scientists having ties with pharma firms

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Legionnaire's disease outbreak in US hospital in New Rochelle 

Genepharm in pact with 3 Australian distributors 

UK has new generics reimbursement scheme 

Teva gets US FDA nod for mirtazapine anti-depressant 

US patent office rejects Pfizer’s Lipitor claims 

Aethlon Medical to start trials on HIV device in India 

Panel to decide fate of Advair, Serevent and Foradil asthma drugs 

Prohibitive costs mar cancer therapy 

FDA directs Palladone withdrawal

Blindness alert on impotence drugs  

Novartis files for breast cancer drug in US, Europe  

Merck readies for $10 billion Vioxx battle  

Speak up on menopause, campaign urges US women 

Direct-To-Consumer ads mislead patients: US Senator  

EU to decide on sops for developing kids drugs  

Zidovudine by Ranbaxy gets US FDA tentative nod

Parkinson's Disease therapy triggers gambling in some patients

Parkinson's Disease symptoms may be relieved by Azilect

Are obesity and diabetes just accelerated aging?

Reducing lung infection and inflammation due to Cystic Fibrosis

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us